Viatris Recalls
25 recalls on record · September 22, 2021 to April 15, 2026 · Drugs
Recalls by year
21
22
23
24
25
26
Count of recall notices naming this brand, by the year the recall was announced. A quiet year is not proof of a safe year.
April 15, 2026DrugsFDA
Viatris, Inc. recalls Xanax XR, alprazolam, extended-release tablets, 3 mg, 60 Tablets bottles, Rx only, Distributed by: Viatris Specialty LLC
Hazard: Failed Dissolution Specifications
January 22, 2025DrugsFDA
Viatris Inc recalls Cardura XL (doxazosin) extended release tablets 4 mg, 30 -count bottle, Rx only, Distributed by Viatris Specialty LLC, M
Hazard: Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
January 22, 2025DrugsFDA
Viatris Inc recalls Cardura XL (doxazosin) extended release tablets 8 mg, 30-count bottle, Rx only, Distributed by Viatris Specialty LLC, Mo
Hazard: Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 112 mcg, packaged in a) 90-count bottles (NDC 0378-1811-77) and b) 1000-count bottles
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 100 mcg, packaged in a) 90-count bottles (NDC 0378-1809-77) and b) 1000-count bottles
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 88 mcg, packaged in a) 90-count bottles (NDC 0378-1807-77) and b) 1000-count bottles (
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-77) and b) 1000-count bottles (
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 50 mcg, packaged in a) 90-count bottles (NDC 0378-1803-77) and b) 1000-count bottles (
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 25 mcg, packaged in a) 90-count bottles (NDC 0378-1800-77) and b) 1000-count bottles (
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 200 mcg, packaged in a) 90-count bottles (NDC 0378-1819-77) and b) 1000-count bottles
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 175 mcg, packaged in a) 90-count bottles (NDC 0378-1817-77) and b) 1000-count bottles
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 150 mcg, packaged in a) 90-count bottles (NDC 0378-1815-77) and b) 1000-count bottles
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 137 mcg, packaged in a) 90-count bottles (NDC 0378-1823-77) and b) 1000-count bottles
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
December 18, 2024DrugsFDA
Viatris Inc recalls Levothyroxine Sodium Tablets USP, 125 mcg, packaged in a) 90-count bottles (NDC 0378-1813-77) and b) 1000-count bottles
Hazard: Superpotent Drug and Subpotent Drug: potency failures obtained
July 24, 2024DrugsFDA
Viatris Inc recalls Cardura XL (doxazosin) extended release tablets 8mg, 30-count bottles, Rx Only Made in Singapore, Distributed by Roerig
Hazard: Failed Impurities/Degradation Specifications
July 24, 2024DrugsFDA
Viatris Inc recalls Cardura XL (doxazosin) extended release tablets 4mg, 30-count bottles, Rx Only, Made in Singapore, Distributed by Roerig
Hazard: Failed Impurities/Degradation Specifications
May 8, 2024DrugsFDA
Viatris Inc recalls Valacyclovir Tablets USP, 500 mg, 90 count bottles, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV
Hazard: Failed Tablet/Capsule Specifications: There is a potential for the imprint, M 122, to be missing on some tablets.
June 14, 2023DrugsFDA
Viatris Inc recalls Levsin injection (hyoscyamine sulfate injection, USP), 0.5 mg per ml in water for Injection, 1 ml Ampule (Box of 5 ampul
Hazard: CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.
November 23, 2022DrugsFDA
Viatris Inc recalls Carvedilol Tablets, USP, 25 mg, 500-count bottles, Rx Only, Mfg: Mylan Pharmaceuticals Inc. Morgantown, WV 36505, Made i
Hazard: Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.
November 16, 2022DrugsFDA
Viatris Inc recalls Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutaneous or Intravenous Use
Hazard: Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.
October 5, 2022DrugsFDA
Viatris Inc recalls Ampicillin for Injection, USP, 2 grams/vial NDC 67457-352-02, packaged in 10 x 2 g vials per carton NDC 67457-352-10, Rx
Hazard: Presence of Particulate Matter: A complaint was received for the presence of a single strand of hair in one vial.
May 18, 2022DrugsFDA
Viatris Inc recalls Xanax XR (alprazolam) extended-release tablets, 3 mg, 60-count bottle, Rx only, Distributed by Pharmacia & Upjohn Co, Di
Hazard: Failed Dissolution Specifications: low out of specification results for dissolution.
May 11, 2022DrugsFDA
Viatris Inc recalls alprazolam XR extended-release tablets, 3 mg, 60-count bottle, Rx only, Distributed by: Greenstone LLC, Peapack, NJ 079
Hazard: Failed Dissolution Specifications: low out-of-specification dissolution test results observed.
October 6, 2021DrugsFDA
Viatris recalls Lyrica CR (pregabalin) extended release tablets, 330 mg, 30-count bottles, Rx only, Distributed by Parke-Davis Division
Hazard: Failed Dissolution Specifications
September 22, 2021DrugsFDA
Viatris recalls Candesartan Cilexetil Tablets, USP 16 mg, 30 count bottles, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV
Hazard: Failed Impurities/Degradation Specifications; out of specification for Related Compound